Loading
A phase 1/2 trial of BI1206 in advanced solid tumours, run by BioInvent International AB, now recruiting.
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04219254 by BioInvent International AB, with 197 participants planned, started 2020-06-29 and due to reach its primary completion in 2027-11. Interventions recorded: BI1206.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/